EBITDA Margin % is calculated as EBITDA divided by its Revenue. PTC Therapeutics's EBITDA for the
three
months ended in Mar. 2026 was €53.6 Mil. PTC Therapeutics's Revenue for the
three
months ended in Mar. 2026 was €235.8 Mil. Therefore, PTC Therapeutics's EBITDA margin for the quarter that ended in Mar. 2026 was 22.74%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
PTC Therapeutics EBITDA Margin % Related Terms
PTC Therapeutics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for PTC Therapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:BH3 vs APGE, MIRM, RYTM: EBITDA Margin % Comparison
For the Biotechnology subindustry, PTC Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PTC Therapeutics EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PTC Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where PTC Therapeutics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PTC Therapeutics (FRA:BH3) has a EBITDA Margin % of 22.74% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PTC Therapeutics and its competitors. According to the industry distribution chart, PTC Therapeutics ranks #323 out of 944 companies in the Biotechnology industry, placing it in the top 34.2%.
Is PTC Therapeutics' EBITDA Margin % too high?
PTC Therapeutics' current EBITDA Margin % is 22.74%. Based on the distribution chart, PTC Therapeutics ranks #323 out of 944 companies in the Biotechnology industry, which is above the industry midpoint. Overall, PTC Therapeutics has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does PTC Therapeutics' EBITDA Margin % compare to APGE and MIRM?
According to the Biotechnology industry distribution chart, PTC Therapeutics ranks #323 out of 944 companies for EBITDA Margin %. This puts PTC Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PTC Therapeutics and its competitors. PTC Therapeutics's current EBITDA Margin % is 22.74%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PTC Therapeutics stock overvalued right now?
PTC Therapeutics (FRA:BH3) has a current EBITDA Margin % of 22.74%. The stock's GF Value™ is €30.00, compared to a current price of €72.26 — trading 140.9% above its estimated fair value. The current EBITDA Margin % is 22.74%. PTC Therapeutics' overall GF Score™ is 51/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For PTC Therapeutics (FRA:BH3), the current EBITDA Margin % is 22.74% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PTC Therapeutics (FRA:BH3) Overvalued in 2026?
Based on GuruFocus' analysis, PTC Therapeutics stock appears to be overvalued.
The current stock price of €72.26 is trading 140.9% above its estimated GF Value™ of €30.00.
Key valuation signals for FRA:BH3:
EBITDA Margin %: 22.74%
GF Value™: €30.00 vs. price of €72.26 (140.9% above fair value)
No single metric tells the full story. See the FRA:BH3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
51GF Score
Get the complete analysis for FRA:BH3
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BH3 has been successfully added to your 
